Career history of Xiao Hui Gu
Former positions of Xiao Hui Gu
Companies | Position | Start | End |
---|---|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 2007-12-31 | 2007-12-31 |
EXELIXIS, INC. | Corporate Officer/Principal | - | - |
PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | 2011-04-30 | - |
Training of Xiao Hui Gu
Hunan Normal University | Undergraduate Degree |
Shanghai Institute of Organic Chemistry | Doctorate Degree |
Statistics
International
China | 4 |
United States | 3 |
Operational
Corporate Officer/Principal | 3 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectoral
Commercial Services | 3 |
Consumer Services | 3 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
PHARMARON BEIJING CO., LTD. | Commercial Services |
EXELIXIS, INC. | Health Technology |
Private companies | 1 |
---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Stock Market
- Insiders
- Xiao Hui Gu
- Experience